Alport syndrome is a genetic condition that damages the kidneys, hearing, and eyes by weakening a key structural protein found in the body’s filtering membranes. It affects roughly 1 in 5,000 to 10,000 people, and because the most common form is X-linked, it hits males earlier and harder. Without treatment, half of affected males develop kidney failure by age 25.
What Goes Wrong at the Cellular Level
Your kidneys filter blood through a thin sheet of tissue called the glomerular basement membrane. In healthy kidneys, this membrane is reinforced by a tough mesh of type IV collagen, built from three protein chains that lock together like a triple-stranded rope. In Alport syndrome, a mutation in any one of the three genes responsible for these chains means none of them can assemble properly. The entire reinforcing network is missing.
Without that network, the basement membrane falls back on an older, weaker version of collagen that the body used during fetal development. This backup mesh has far fewer chemical crosslinks holding it together, making it thinner and more vulnerable to being chewed up by enzymes. Over time, the filter breaks down. Protein and blood leak through into the urine, and scar tissue gradually replaces healthy kidney tissue.
The same type of collagen lines structures in the inner ear and the eye, which is why Alport syndrome affects all three organs.
Inheritance Patterns
About 85% of Alport syndrome cases follow an X-linked pattern, meaning the mutation sits on the X chromosome. Because males have only one X chromosome, a single copy of the faulty gene is enough to cause the full disease. Females carry two X chromosomes, so their healthy copy partially compensates. They can still develop symptoms, but kidney failure typically arrives decades later, if at all.
The remaining 10 to 15% of cases are autosomal recessive, requiring a defective gene from both parents. A small number of families carry an autosomal dominant form, where one copy of the mutation is enough to cause disease regardless of sex. Both of these rarer forms involve different genes but damage the same collagen network in the same way.
Kidney Symptoms and Progression
The earliest sign is blood in the urine, often detectable only under a microscope. In boys with X-linked Alport syndrome, this can appear in infancy or early childhood. For years it may be the only abnormality, which is one reason the condition sometimes goes undiagnosed until protein starts showing up in the urine as well.
Rising protein in the urine signals that the kidney’s filter is deteriorating. From there, kidney function declines steadily. In untreated males with the X-linked form, about 50% reach kidney failure by age 25, 90% by age 40, and nearly all by age 60. The pace depends partly on the type of mutation: large deletions and certain severe mutations tend to cause faster progression, while milder mutations can push kidney failure into the 30s or beyond. Females with one affected X chromosome usually maintain kidney function much longer, though some do eventually develop significant kidney disease later in life.
Hearing Loss
About 80% of people with Alport syndrome develop sensorineural hearing loss, meaning the problem originates in the inner ear rather than the ear canal or eardrum. It typically starts in the early teenage years, first affecting high-pitched sounds and gradually working down into lower frequencies. By the late 20s, the loss often reaches a moderate level. Hearing aids are effective because the auditory nerve itself still works; the issue is the damaged collagen in the structures of the inner ear that transmit sound vibrations.
Hearing loss is not present at birth, so a normal newborn hearing screen does not rule out Alport syndrome. Regular audiometry starting in childhood is important for anyone known to carry the mutation.
Eye Involvement
Around 40% of people with Alport syndrome develop eye abnormalities. The most distinctive is anterior lenticonus, a condition where the front surface of the lens bulges forward into a cone shape because the collagen capsule holding the lens in place is too weak. On a slit-lamp exam, this creates a characteristic “oil droplet” appearance. Anterior lenticonus is so specific to Alport syndrome that finding it essentially confirms the diagnosis.
A more common finding is dot-and-fleck retinopathy, a scattering of tiny pigment changes around the central retina or in the periphery. This usually does not affect vision and does not need treatment, but peripheral retinal changes tend to show up alongside earlier-stage kidney disease, making them a useful clinical clue.
How Alport Syndrome Is Diagnosed
Genetic testing is now the most definitive way to diagnose Alport syndrome. It picks up X-linked cases with at least 90% sensitivity and can identify the exact mutation, which helps predict how fast kidney disease will progress. This matters because certain mutation types (deletions, nonsense mutations, splicing errors) are linked to kidney failure before age 30.
Kidney biopsy was historically the standard diagnostic tool, but it has significant limitations. In early stages, the biopsy may look normal or mimic other kidney diseases, leading to misdiagnosis. Even specialized staining for type IV collagen catches only about 80% of affected males and 60% of affected females. For these reasons, genetic testing has increasingly replaced biopsy as the first-line diagnostic approach, especially when there is a family history of blood in the urine, hearing loss, or unexplained kidney failure.
Treatment: Slowing Kidney Damage
There is no cure for Alport syndrome, but treatment can significantly delay kidney failure. The cornerstone is a class of blood pressure medications called ACE inhibitors. These drugs reduce the pressure inside the kidney’s filtering units and lower the amount of protein leaking into the urine, which in turn slows scarring. Retrospective data strongly suggest that starting ACE inhibitor therapy while kidney function is still well preserved delays the onset of kidney failure by years.
Clinical guidelines recommend monitoring urine for protein starting by age 1 in children known to be at risk, with testing repeated at least annually. Treatment is initiated once persistent protein is detected in the urine. For boys carrying high-risk mutations or with a family history of early kidney failure, doctors may take an especially aggressive approach, starting medication and escalating doses to suppress protein leakage as much as possible.
If ACE inhibitors alone are not enough, a second medication can be added. Options include angiotensin receptor blockers or aldosterone blockers, both of which target the same hormonal system from different angles. In small studies, the combination of an ACE inhibitor with an aldosterone blocker suppressed protein in the urine more effectively than pairing an ACE inhibitor with an angiotensin receptor blocker.
Kidney Transplant
When kidney failure does occur, transplantation is the preferred treatment and generally works well. Transplanted kidneys contain normal type IV collagen, so the underlying structural defect does not recur in the new organ. However, there is one unique risk: because the recipient’s immune system has never encountered normal collagen chains, it can sometimes recognize them as foreign and mount an attack against the transplanted kidney’s basement membrane. This complication, called post-transplant anti-GBM nephritis, occurs in roughly 2 to 3% of males with X-linked Alport syndrome. It can cause rapid graft failure, but the low incidence means it does not change the overall recommendation in favor of transplantation.
Living-related donors are often considered, but family members need genetic testing first. A relative who carries the same mutation, even without symptoms, would not be an appropriate donor because their own kidneys may eventually be affected.